

SUPPLEMENTAL MATERIAL

Murray et al., <https://doi.org/10.1084/jem.20161988>

Table S1. Summary of CD8 T cell responses to vaccination

Subject	Chimera/ dose (PFU)	IE-1 15mer response	Core epitopes	Defined HLA restriction ^a	Potential HLA restriction	HLA
23	4/10 ²	22	QIKVRVDMV	B08		A1:01; B8:01; C7:01
36	4/10 ³	49	ELKRKMMYM	B08		A1:01,32:01; B8:01,18:01; C7:01
		22	QIKVRVDMV	B08		
		49–50	ELKRKMMYM	~10% B08	B18 ^b	
24	4/10 ²	75	GAISLLTEF	Cw3		A2:01,68:02; B44:03,82:01; C3:02,3:03
		28	2/10 ³	24–25	RIKEHMLKK	
28	2/10 ³	79	EETSVMLAK		A68 ^c	
		79–81	nd			
30	2/10 ³	51–52	YMCYRNIEF	A2		A2:01,29:02; B44:02,44:03; C5:01,16:01
34	4/10 ³	68	nd	A2		A2:01,33:01; B14:02,18:01; C7:01,8:02
		49–50 ^d	DELKRKMMY		B18 ^b	

Abbreviation used: nd, not determined.

^aAssessed by peptide pulsing single HLA transfectants.

^bBased on predicted IC50 of 505.8 nM for binding of DELKRKMM to HLA-B18:01, predicted IC50 of 199.5 nM for binding of DELKRKMMYM to HLA-B18:01, and predicted IC50 of 96.7 nM for binding of DELKRKMMY to HLA-B18:01 (<http://tools.iedb.org/main/>; Hoof et al., 2009).

^cBased on preference of HLA-A68, but not other MHC Ia molecules, for a C' lysine (Guo et al., 1992) and predicted IC50 of 14.5 nM for binding of ETSVMLAK to HLA-A68:01 (<http://tools.iedb.org/main/>; Hoof et al., 2009).

^dThe response of subject 34 to the DY9 peptide was not characterized with respect to MHC II or HLA-E restriction because the T cell line could not be maintained.

REFERENCES

Guo, H.-C., T.S. Jardetzky, T.P. Garrett, W.S. Lane, J.L. Strominger, and D.C. Wiley. 1992. Different length peptides bind to HLA-Aw68 similarly at their ends but bulge out in the middle. *Nature*. 360:364–366. <http://dx.doi.org/10.1038/360364a0>

Hoof, I., B. Peters, J. Sidney, L.E. Pedersen, A. Sette, O. Lund, S. Buus, and M. Nielsen. 2009. NetMHCpan, a method for MHC class I binding prediction beyond humans. *Immunogenetics*. 61:1–13. <http://dx.doi.org/10.1007/s00251-008-0341-z>